Oppenheimer assumed coverage of Nurix Therapeutics with an Outperform rating and $25 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NRIX:
- Nurix Therapeutics assumed with an Outperform at Oppenheimer
- Nurix Therapeutics presents data on NX-5948, NX-2127
- Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
- Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference